Palvella Therapeutics will unveil its third QTORIN™ product candidate during a live webcast on November 19, 2026.
Quiver AI Summary
Palvella Therapeutics, Inc. announced that it will host a live webcast on November 19, 2026, at 8:30 a.m. ET to unveil its third product candidate from the QTORIN™ platform. The company, focused on developing therapies for serious, rare skin diseases and vascular anomalies, aims to address conditions that currently lack FDA-approved treatments. Details for accessing the webcast will be provided in a prior press release and on Palvella's website, with a replay available for 90 days afterward. Palvella is developing multiple product candidates, including QTORIN™ 3.9% rapamycin anhydrous gel and QTORIN™ pitavastatin, both of which are investigational and not yet FDA-approved.
Potential Positives
- Palvella is set to announce a third product candidate from its promising QTORIN™ platform, potentially expanding its pipeline of rare disease therapies.
- The live webcast presentation indicates proactive engagement with stakeholders and may enhance investor interest and public awareness of the company’s developments.
- Palvella’s focus on serious, rare skin diseases and vascular anomalies positions it uniquely in a niche market with unmet medical needs.
Potential Negatives
- Palvella's press release does not provide any new data or insights regarding the efficacy or safety of their product candidates, which could be seen as a lack of transparency or progress.
- The announcement focuses on a webcast rather than substantial developments or results, potentially causing disappointment among investors seeking concrete progress on regulatory approvals or clinical trial outcomes.
- There is a heavy emphasis on forward-looking statements, which may highlight the uncertainty and risks facing Palvella, potentially shaking investor confidence in the company's future performance.
FAQ
What is the QTORIN™ platform?
The QTORIN™ platform is Palvella's proprietary technology for developing therapies for serious, rare skin diseases and vascular anomalies.
When will the new QTORIN™ candidate be announced?
The announcement of the new QTORIN™ candidate is scheduled for Thursday, November 19, 2026, at 8:30 a.m. ET.
How can I access the live webcast?
Access details for the live webcast will be provided in a press release and on Palvella's website.
What are Palvella's main focuses in drug development?
Palvella focuses on developing novel therapies for rare skin diseases and vascular anomalies lacking FDA-approved treatments.
How long will the webcast replay be available?
The webcast replay will be archived on Palvella's website for 90 days following the live event.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$PVLA Insider Trading Activity
$PVLA insiders have traded $PVLA stock on the open market 58 times in the past 6 months. Of those trades, 0 have been purchases and 58 have been sales.
Here’s a breakdown of recent trading of $PVLA stock by insiders over the last 6 months:
- GEORGE M JENKINS has made 0 purchases and 26 sales selling 55,000 shares for an estimated $7,746,622.
- KATHLEEN GOIN (Chief Operating Officer) has made 0 purchases and 18 sales selling 21,521 shares for an estimated $2,965,585.
- JEFFREY S MARTINI (Chief Scientific Officer) has made 0 purchases and 13 sales selling 12,500 shares for an estimated $2,083,076.
- CHRISTOPHER P KIRITSY sold 313 shares for an estimated $49,141
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$PVLA Hedge Fund Activity
We have seen 110 institutional investors add shares of $PVLA stock to their portfolio, and 101 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM removed 1,693,252 shares (-99.3%) from their portfolio in Q3 2026, for an estimated $233,550,248
- WESTFIELD CAPITAL MANAGEMENT CO LP added 396,045 shares (+inf%) to their portfolio in Q3 2026, for an estimated $54,626,486
- MARSHALL WACE, LLP added 326,947 shares (+11463.8%) to their portfolio in Q3 2026, for an estimated $45,095,799
- INVESCO LTD. added 279,077 shares (+829.3%) to their portfolio in Q3 2026, for an estimated $38,493,090
- FRONTIER CAPITAL MANAGEMENT CO LLC removed 202,561 shares (-42.3%) from their portfolio in Q3 2026, for an estimated $27,939,238
- WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC added 195,070 shares (+inf%) to their portfolio in Q3 2026, for an estimated $26,906,005
- ARTISAN PARTNERS LIMITED PARTNERSHIP removed 193,796 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $29,615,904
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$PVLA Analyst Ratings
Wall Street analysts have issued reports on $PVLA in the last several months. We have seen 6 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Leerink Partners issued a "Outperform" rating on 11/16/2026
- Canaccord Genuity issued a "Buy" rating on 11/09/2026
- Oppenheimer issued a "Outperform" rating on 11/06/2026
- Chardan Capital issued a "Buy" rating on 10/28/2026
- William Blair issued a "Outperform" rating on 10/16/2026
- HC Wainwright & Co. issued a "Buy" rating on 10/12/2026
To track analyst ratings and price targets for $PVLA, check out Quiver Quantitative's $PVLA forecast page.
$PVLA Price Targets
Multiple analysts have issued price targets for $PVLA recently. We have seen 5 analysts offer price targets for $PVLA in the last 6 months, with a median target of $240.0.
Here are some recent targets:
- Jenny Gonzalez-Armenta from Leerink Partners set a target price of $228.0 on 11/16/2026
- Whitney Ijem from Canaccord Genuity set a target price of $243.0 on 11/09/2026
- Trevor Allred from Oppenheimer set a target price of $232.0 on 11/06/2026
- Gautam Chukka from Chardan Capital set a target price of $240.0 on 10/28/2026
- Andrew S. Fein from HC Wainwright & Co. set a target price of $246.0 on 10/12/2026
Full Release
Third product candidate from Palvella’s QTORIN™ platform to be announced
Live audiovisual webcast to take place tomorrow, Thursday, November 19, 2026, at 8:30 a.m. ET
WAYNE, Pa., Nov. 18, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Nasdaq: PVLA) (“Palvella” or the “Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare skin diseases and vascular anomalies for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced that it will host a live, presentation-only webcast tomorrow, Thursday, November 19, 2026, at 8:30 a.m. ET to announce a new QTORIN™ program, the third product candidate from the Company’s QTORIN™ platform. Webcast access details will be included in a press release issued prior to the event and in the “Events & Presentations” section of the Company’s website at www.palvellatx.com . A replay will be archived on the Company’s website for 90 days following the event.
About Palvella Therapeutics
Founded and led by rare disease biotech veterans, Palvella Therapeutics, Inc. (Nasdaq: PVLA) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients living with serious, rare skin diseases and vascular anomalies for which there are no FDA-approved therapies. Palvella is developing a broad pipeline of product candidates based on its patented QTORIN™ platform, with an initial focus on serious, rare skin diseases and vascular anomalies, many of which are lifelong in nature. Palvella’s lead product candidate, QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin), is currently being developed for the treatment of microcystic lymphatic malformations, cutaneous venous malformations, and clinically significant angiokeratomas. Palvella’s second product candidate, QTORIN™ pitavastatin, is currently being developed for the treatment of disseminated superficial actinic porokeratosis. For more information, please visit www.palvellatx.com or follow Palvella on LinkedIn or X (formerly known as Twitter).
QTORIN™ rapamycin and QTORIN™ pitavastatin are for investigational use only and neither has been approved by the FDA or by any other regulatory agency for any indication.
Forward-Looking Statements
This press release contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended (Securities Act)). These statements may discuss goals, intentions, and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the management of Palvella, as well as assumptions made by, and information currently available to, the management of Palvella. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” and other similar expressions or the negative or plural of these words, or other similar expressions that are predictions or indicate future events or prospects, although not all forward-looking statements contain these words. Statements that are not historical facts are forward-looking statements. Forward-looking statements include, but are not limited to, statements regarding the expected timing of the presentation of data from clinical trials, Palvella’s clinical development plans and related anticipated development milestones and anticipated timing of regulatory submissions, Palvella’s expectations with respect to the potential approval of the NDA for QTORIN™ rapamycin, the potential impact of Priority Review on the FDA’s review timeline, any delays in the FDA’s review of Palvella’s accepted NDA, Palvella’s commercial preparedness and the timing and execution of a potential launch following regulatory approval, Palvella’s plans to pursue Breakthrough Therapy Designation, Palvella’s plans to meet with regulatory authorities, Palvella’s expectations regarding the benefits of orphan drug designation and potential benefit of orphan drug exclusivity for QTORIN™ rapamycin for the treatment of microcystic lymphatic malformations, Palvella’s cash, financial resources and expected runway, Palvella’s expectations regarding its programs, including QTORIN™ rapamycin and QTORIN™ pitavastatin, and its research-stage opportunities, including its expected therapeutic potential and market opportunity. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the ability to raise additional capital to finance operations; the ability to advance product candidates through preclinical and clinical development; the ability to make regulatory submissions on anticipated timelines; the ability to obtain regulatory approval for, and ultimately commercialize, Palvella’s product candidates, including QTORIN™ rapamycin and QTORIN™ pitavastatin; the outcome of early clinical trials for Palvella’s product candidates, including the ability of those trials to satisfy relevant governmental or regulatory requirements; the fact that data and results from clinical studies may not necessarily be indicative of future results; Palvella’s limited experience in designing clinical trials and lack of experience in conducting clinical trials; Palvella’s limited experience in commercial manufacturing; the ability to identify and pivot to other programs, product candidates, or indications that may be more profitable or successful than Palvella’s current product candidates; the substantial competition Palvella faces in discovering, developing, or commercializing products; the negative impacts of global events on operations, including ongoing and planned clinical trials and ongoing and planned preclinical studies; the ability to attract, hire, and retain skilled executive officers and employees; the ability of Palvella to protect its intellectual property and proprietary technologies; reliance on third parties, contract manufacturers, and contract research organizations; and the risks and uncertainties described in the filings made by Palvella with the Securities and Exchange Commission (SEC), including the annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, filed with or furnished to the SEC and available at www.sec.gov. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that Palvella may face. Except as required by applicable law, Palvella does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. This press release contains hyperlinks to information that is not deemed to be incorporated by reference into this press release.
Contact Information
Investors
Wesley H. Kaupinen
Founder and CEO
Palvella Therapeutics
[email protected]
Media
Marcy Nanus
Vice President of Investor Relations and Corporate Affairs
Palvella Therapeutics
[email protected]